Vivalis and Intercell Merge to form Valneva
News May 29, 2013
Valneva SE announces the completion of the merger of equals between Vivalis and Intercell, creating a new European biotech company focusing on vaccines and antibodies, striving to become a leader in its field.
Valneva ordinary shares (ISIN FR0004056851) start trading today on the regulated market of NYSE Euronext in Paris under the ticker symbol “VLA.PA” and on the Prime Market segment of the Vienna Stock Exchange under the ticker symbol “VLA”. Valneva preferred shares (ISIN FR0011472943) will start trading today on the regulated market of NYSE Euronext in Paris under ticker symbol “VLApr.PA” and on the unregulated Third Market Segment of the Vienna Stock Exchange under the ticker symbol “VLAP”.
Thomas Lingelbach, President and Chief Executive Officer and Franck Grimaud, President and Chief Business Officer of Valneva, commented: “Today is a major milestone for our new company. Valneva combines the strengths and capabilities of Vivalis and Intercell in antibody discovery and vaccine development and commercialization. We have a clear growth strategy to build a sustainable business by growing revenues through marketed products as well as through existing and future partnerships, and to invest into vaccines development and antibody discovery. We believe this value proposition will generate substantial rewards for our shareholders.”
Valneva operates across the whole biopharmaceutical value chain with innovative technology platforms, discovery and development capabilities, state-of-the-art manufacturing and commercialization expertise. Valneva generates revenue from diversified sources including its marketed product as well as current and new commercial partnerships. Valneva has a broad portfolio of product candidates (in-house/partnered) including a pandemic Influenza vaccine in Phase III, a Pseudomonas vaccine in Phase II/III and a Tuberculosis vaccine in Phase II.
It has also a portfolio of technology platforms that are becoming widely adopted by the biopharmaceutical industry at large. These include the validated and commercialized technology platforms EB66® cell line for human and veterinary product development, VIVA|ScreenTM antibody discovery platform and IC31® novel adjuvant.
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Brillouin Microscopy: Emerging Tool for Probing Mechanical Properties of Living Cells
Jan 17 - Jan 19, 2018